Value through Innovation27 July 2016

Clinical Study Results

  • MICARDIS ® - Diabetic Nephropathies
    Clinical Study Number 502.396
    Study Indication Diabetic Nephropathies
    Product MICARDIS ®
    Generic Name Telmisartan
    Lab Code
    Clinical Phase IV
    Study Title

    A prospective, randomised, double-blind, double-dummy, forced-titration, multicentre, parallel group, one year treatment trial to investigate the efficacy of Telmisartan 80 mg versus Valsartan 160 mg in hypertensive type 2 diabetic patients with overt nephropathy - VIVALDI-Study

    Study Document Trial synopsis 502.396_CO english
  • MICARDIS ® - Diabetic Nephropathies
    Clinical Study Number 502.413
    Study Indication Diabetic Nephropathies
    Product MICARDIS ®
    Generic Name Telmisartan
    Lab Code
    Clinical Phase III
    Study Title

    A randomised, double-blind, placebo-controlled, multicenter trial to investigate the preventive effect of BIBR277 (telmisartan) in diabetic nephropathy on transition from incipient to overt nephropathy. - Incipient to overt: angiotensin 2 receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION Study)

    Study Document Trial synopsis 502.413_CO english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.